

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/648,786
				Filing Date	August 27, 2003
				First Named Inventor	NI, Jian
				Art Unit	1646
				Examiner Name	Kaufman, Claire M.
Sheet	1	of	2	Attorney Docket Number	1488.130000B/EJH/SAC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL1	Delgi-Esposti, M.A., <i>et al.</i> , "Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family," <i>J. Exp. Med.</i> 186:1165-1170, Rockefeller University Press (October 1997)	
	NPL2	Locksley, R.M., <i>et al.</i> , "The TNF and TNF Receptor Superfamilies: Integrating Mammalian Biology," <i>Cell</i> 104:487-501, Cell Press (February 2001)	
	NPL3	MacFarlane, M., "Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL," <i>J. Biol. Chem.</i> 272:25417-25420, American Society for Biochemistry and Molecular Biology (October 1997)	
	NPL4	Marsters, S.A., <i>et al.</i> , "A novel receptor for Apo2L/TRAIL contains a truncated death domain," <i>Curr. Biol.</i> 7:1003-1006, Cell Press (December 1997)	
	NPL5	Pan, G., <i>et al.</i> , "An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL," <i>Science</i> 277:815-818, American Association for the Advancement of Science (August 1997)	
	NPL6	Schneider, P., <i>et al.</i> , "Characterization of two receptors for TRAIL," <i>FEBS Lett.</i> 416:329-334, Elsevier Science B.V. (October 1997)	
	NPL7	Screaton, G.R., <i>et al.</i> , "TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL," <i>Curr. Biol.</i> 7:693-696, Cell Press (September 1997)	
	NPL8	Sheridan, J.P., <i>et al.</i> , "Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors," <i>Science</i> 277:818-821, American Association for the Advancement of Science (August 1997)	
	NPL9	Simonet, W.S., <i>et al.</i> , "Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density," <i>Cell</i> 89:309-319, Cell Press (April 1997)	
	NPL10	Tsuda, E., <i>et al.</i> , "Isolation of a Novel Cytokine from Human Fibroblasts That Specifically Inhibits Osteoclastogenesis," <i>Biochem. Biophys. Res. Commun.</i> 234:137-142, Academic Press (May 1997)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CK/
If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/648,786
				Filing Date	August 27, 2003
				First Named Inventor	NI, Jian
				Art Unit	1646
				Examiner Name	Kaufman, Claire M.
Sheet	2	of	2	Attorney Docket Number	1488.130000B/EJH/SAC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL11	Wallach, D., <i>et al.</i> , "Tumor Necrosis Factor Receptor and <i>Fas</i> Signaling Mechanisms," <i>Annu. Rev. Immunol.</i> 17:331-367, Annual Reviews (April 1999)	
	NPL12	Ware, C.F., <i>et al.</i> , "Apoptosis Mediated by the TNF-Related Cytokine and Receptor Families," <i>J. Cell. Biochem.</i> 60:47-55, Wiley-Liss (January 1996)	
	NPL13	European Opposition Document for European Patent No. 1 012 274, Communication of a notice of opposition, 1 page, dated March 28, 2008	
	NPL14	European Opposition Document for European Patent No. 1 012 274, Communication of a notice of opposition, 1 page, dated March 7, 2008	
	NPL15	Opposition to European Patent No. 1 012 274 B, filed by Genentech, Inc. in the European Patent Office, 23 pages, dated February 27, 2008	

815624v1

Examiner Signature	/Claire Kaufman/	Date Considered	07/07/2008
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CK/
 If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.